New MRI contrast agent could improve liver lesion detection
NCT ID NCT06596616
First seen May 14, 2026 · Last updated Jun 22, 2026 · Updated 8 times
Summary
This study compares a new contrast agent called gadopiclenol to the standard agent gadoxetate for liver MRI scans. Researchers want to see if gadopiclenol is as good or better at detecting liver lesions. The study involves 23 adults with chronic liver disease or known liver lesions who need an MRI.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER LESION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BMEII
New York, New York, 10029, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gadopiclenol (a gadolinium-based contrast agent for MRI)
What this could lead to
If successful, this could show that gadopiclenol is a safe and effective alternative to gadoxetate for liver MRI, potentially improving image quality and lesion detection.
What could go wrong
This is a small, early-phase study with only 23 participants, so results may not apply to everyone. The comparison is about image quality, not a new treatment or cure.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.